Nuvation Bio Inc (NUVB) - Total Liabilities
Based on the latest financial reports, Nuvation Bio Inc (NUVB) has total liabilities worth $490.64 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore NUVB long-term investments to assets to see how much of total assets are deployed in long-term investments.
Nuvation Bio Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Nuvation Bio Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Nuvation Bio Inc.
Nuvation Bio Inc Competitors by Total Liabilities
The table below lists competitors of Nuvation Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chalet Hotels Limited
NSE:CHALET
|
India | Rs35.59 Billion |
|
Resolute Mining Ltd
AU:RSG
|
Australia | AU$498.14 Million |
|
NRW Holdings Limited
F:3NR
|
Germany | €1.09 Billion |
|
Chongqing Fuling Electric Power Industrial Co Ltd
SHG:600452
|
China | CN¥731.84 Million |
|
OKE Precision Cutting Tools Co. Ltd. A
SHG:688308
|
China | CN¥1.26 Billion |
|
Perdoceo Education Corp
NASDAQ:PRDO
|
USA | $301.53 Million |
|
Xinjiang Joinworld Co Ltd
SHG:600888
|
China | CN¥7.50 Billion |
|
John Wiley & Sons
NYSE:WLY
|
USA | $1.81 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Nuvation Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See NUVB equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.93 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nuvation Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nuvation Bio Inc (2018–2025)
The table below shows the annual total liabilities of Nuvation Bio Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $289.11 Million | +276.25% |
| 2024-12-31 | $76.84 Million | +369.61% |
| 2023-12-31 | $16.36 Million | -4.12% |
| 2022-12-31 | $17.07 Million | -43.41% |
| 2021-12-31 | $30.15 Million | +349.52% |
| 2020-12-31 | $6.71 Million | +109.36% |
| 2019-12-31 | $3.20 Million | +255.21% |
| 2018-12-31 | $902.00K | -- |
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the ma… Read more